PMID- 24373869
OWN - NLM
STAT- MEDLINE
DCOM- 20141031
LR  - 20191210
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 63
IP  - 4
DP  - 2014 Apr
TI  - Safety and efficacy of adaptive servo-ventilation in patients with severe 
      systolic heart failure.
PG  - 302-7
LID - S0914-5087(13)00287-6 [pii]
LID - 10.1016/j.jjcc.2013.09.008 [doi]
AB  - BACKGROUND AND PURPOSE: It is unclear whether adaptive servo-ventilation (ASV) is 
      safe and effective in patients with severe systolic heart failure (HF). Our aim 
      in this study was to estimate the safety and efficacy of ASV therapy for patients 
      with severe systolic HF. METHODS AND SUBJECTS: Seventy-six HF patients (age: 
      69+/-12 years; 53 men), categorized as New York Heart Association (NYHA) Class 
      II-IV, with left ventricular ejection fraction (LVEF) of <50%, received ASV 
      therapy after optimal medical therapy to determine the safety and efficacy of 
      ASV. Patients were divided into 2 groups based on their LVEF: group L (LVEF<30%; 
      n=42) and group H (LVEF>/=30%; n=34). After 6 months of ASV therapy, we compared 
      the changes in LVEF, brain natriuretic peptide (BNP), and incidence of fatal 
      cardiovascular events between the groups. RESULTS: The groups differed 
      significantly with respect to beta-blocker treatment before ASV therapy 
      (p<0.0001). After 6 months of ASV therapy, LVEF and BNP levels had improved in 
      both groups. In group L, LVEF had improved from 24.1+/-5.6% to 35.2+/-10.6% 
      (p<0.0001) and BNP from 591 (273-993)pg/ml to 142 (39-325)pg/ml (p=0.002). 
      Moreover, 1-year follow-up data showed a tendency toward improvement of NYHA 
      classification in group L (group L: 50%; group H: 29%; p=0.07), and showed no 
      significant difference with regard to fatal cardiovascular events between the 2 
      groups (group L: 11.9%; group H: 5.9%; p=0.36). CONCLUSIONS: Our study 
      demonstrated that ASV therapy is safe and effective for use in very severe 
      systolic HF patients as well as in relatively mild systolic HF patients.
CI  - Copyright (c) 2013. Published by Elsevier Ltd.
FAU - Takama, Noriaki
AU  - Takama N
AD  - Department of Cardiovascular Medicine, Gunma University School of Medicine, 
      Maebashi, Japan. Electronic address: goritakama@db3.so-net.ne.jp.
FAU - Kurabayashi, Masahiko
AU  - Kurabayashi M
AD  - Department of Cardiovascular Medicine, Gunma University School of Medicine, 
      Maebashi, Japan.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20131225
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Biomarkers)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - Cardiovascular Diseases/epidemiology
MH  - Female
MH  - Heart Failure/*therapy
MH  - Heart Failure, Systolic/diagnosis/physiopathology/*therapy
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Respiration, Artificial/*methods
MH  - Safety
MH  - Severity of Illness Index
MH  - Stroke Volume
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adaptive servo-ventilation
OT  - Heart failure
OT  - Sleep-disordered breathing
EDAT- 2014/01/01 06:00
MHDA- 2014/11/02 06:00
CRDT- 2013/12/31 06:00
PHST- 2013/05/05 00:00 [received]
PHST- 2013/09/07 00:00 [revised]
PHST- 2013/09/13 00:00 [accepted]
PHST- 2013/12/31 06:00 [entrez]
PHST- 2014/01/01 06:00 [pubmed]
PHST- 2014/11/02 06:00 [medline]
AID - S0914-5087(13)00287-6 [pii]
AID - 10.1016/j.jjcc.2013.09.008 [doi]
PST - ppublish
SO  - J Cardiol. 2014 Apr;63(4):302-7. doi: 10.1016/j.jjcc.2013.09.008. Epub 2013 Dec 
      25.